Skip to content
Home » Pediatric Urology » Rhabdomyosarcoma

Rhabdomyosarcoma

Arises from undifferentiated mesenchymal tissue.

10 – 15 % of solid tumours in children.

20 – 30 % of rhabdomyosarcomas arise from genitourinary tract – bladder, prostate, vagina, uterus or paratesticular.

Bimodal distribution – 2-4 years, then 15 – 19 years.

Majority are sporadic – but associated with Li Fraumeni or neurofibromatosis type 1.

Other risk factors – high birth weight, LGA, advanced maternal age, maternal drug use

 

Pathology

Two main categories – embryonal and alveolar – majority of GU tumours are embryonal (better prognosis cf. alveolar)

Typical characteristic feature is early differentiation towards skeletal muscle phenotype.

Described as ‘botryoid’ variant – like a bunch of grapes.

Disseminates mostly by local spread – lymphatic (20 %) and metastasis (10 %) less common.

 

Presentation

May be variable:

  • Urinary symptoms or urinary retention, haematuria, constipation
  • Abdominal pain or mass
  • Paratesticular/scrotal painless mass
  • Protruding botryoid vaginal mass

 

Work up and investigation

Usually appropriate imaging – CT, MRI, chest imaging, ultrasound.

Bloods including FBC and renal function.

Biopsy – percutaneously, or transurethrally, depending on circumstances.

Assess for metastatic disease – locoregional LNs.

 

 

 

Management

Multidisciplinary

Usually initially treated with chemotherapy – various combinations of vincristine, actinomycin, cyclophosphamide and ifosfamide.

Radiation including brachytherapy may be used post-operative for residual disease or difficult to operate cases.

Surgery, usually following chemo, may be organ sparing or radical depending on site.

  • Radical inguinal orchidectomy for paratesticular cases.
  • Partial cystectomy vs cystectomy vs cystoprostatectomy

 

Prognostic factors:

> 10 years at presentation is worse

Embryonal variant is better than alveolar

Vaginal/paratesticular better prognosis than bladder/prostate

Larger tumours / higher stage worse, involved lymph nodes worse

PAX/FOXO1 genes on histology associated with worse survival.

Overall survival around 80 % for prostate/bladder, better for paratesticular.

 

Bladder sparing surgery may be associated with significant morbidity in terms of urinary symptoms and incontinence.